345 related articles for article (PubMed ID: 28105889)
1. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.
Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJG; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
Hematology; 2017 Aug; 22(7):405-411. PubMed ID: 28105889
[TBL] [Abstract][Full Text] [Related]
2. Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era.
Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJ; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
Br J Haematol; 2016 Oct; 175(2):275-280. PubMed ID: 27443247
[TBL] [Abstract][Full Text] [Related]
3. Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era.
Perrone S; D'Elia GM; Annechini G; Ferretti A; Tosti ME; Foà R; Pulsoni A
Leuk Res; 2016 May; 44():53-60. PubMed ID: 27030961
[TBL] [Abstract][Full Text] [Related]
4. Risk adapted approach: How to treat splenic marginal zone lymphoma in resource-poor settings? - The real-life experience of a Brazilian cancer treatment center.
de Pádua Covas Lage LA; Dos Santos FFC; Levy D; Moreira FR; Couto SCF; Culler HF; de Oliveira Costa R; Rocha V; Pereira J
BMC Cancer; 2020 Aug; 20(1):717. PubMed ID: 32746790
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment.
Lenglet J; Traullé C; Mounier N; Benet C; Munoz-Bongrand N; Amorin S; Noguera ME; Traverse-Glehen A; Ffrench M; Baseggio L; Felman P; Callet-Bauchu E; Brice P; Berger F; Salles G; Brière J; Coiffier B; Thieblemont C
Leuk Lymphoma; 2014 Aug; 55(8):1854-60. PubMed ID: 24206091
[TBL] [Abstract][Full Text] [Related]
6. Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia.
Xing KH; Kahlon A; Skinnider BF; Connors JM; Gascoyne RD; Sehn LH; Savage KJ; Slack GW; Shenkier TN; Klasa R; Gerrie AS; Villa D
Br J Haematol; 2015 May; 169(4):520-7. PubMed ID: 25854936
[TBL] [Abstract][Full Text] [Related]
7. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma.
Olszewski AJ; Ali S
Ann Hematol; 2014 Mar; 93(3):449-58. PubMed ID: 24057925
[TBL] [Abstract][Full Text] [Related]
8. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma.
Else M; Marín-Niebla A; de la Cruz F; Batty P; Ríos E; Dearden CE; Catovsky D; Matutes E
Br J Haematol; 2012 Nov; 159(3):322-8. PubMed ID: 23016878
[TBL] [Abstract][Full Text] [Related]
9. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients.
Zhang T; Wu Y; Ju H; Meng J; Guo W; Ren G
Cancer Med; 2020 Jan; 9(1):194-203. PubMed ID: 31733094
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
[TBL] [Abstract][Full Text] [Related]
11. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
Bennett M; Schechter GP
Semin Hematol; 2010 Apr; 47(2):143-7. PubMed ID: 20350661
[TBL] [Abstract][Full Text] [Related]
12. Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up.
Cervetti G; Galimberti S; Pelosini M; Ghio F; Cecconi N; Petrini M
Ann Oncol; 2013 Sep; 24(9):2434-8. PubMed ID: 23712547
[TBL] [Abstract][Full Text] [Related]
13. How to treat splenic marginal zone lymphoma (SMZL) in patients unfit for surgery or more aggressive therapies: experience in 30 cases.
Cervetti G; Ghio F; Cecconi N; Morganti R; Galimberti S; Petrini M
J Chemother; 2017 Apr; 29(2):126-129. PubMed ID: 27454143
[TBL] [Abstract][Full Text] [Related]
14. Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study.
Iannitto E; Luminari S; Tripodo C; Mancuso S; Cesaretti M; Marcheselli L; Merli F; Stelitano C; Carella AM; Fragasso A; Montechiarello E; Ricciuti G; Pulsoni A; Paulli M; Franco V; Federico M
Leuk Lymphoma; 2015; 56(12):3281-7. PubMed ID: 25791121
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics of 95 patients with ocular adnexal and uveal lymphoma: treatment outcomes in extranodal marginal zone subtype.
Portell CA; Aronow ME; Rybicki LA; Macklis R; Singh AD; Sweetenham JW
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):203-10. PubMed ID: 24417911
[TBL] [Abstract][Full Text] [Related]
16. Still a role for surgery as first-line therapy of splenic marginal zone lymphoma? Results of a prospective observational study.
Pata G; Bartoli M; Damiani E; Solari S; Anastasia A; Pagani C; Tucci A
Int J Surg; 2017 May; 41():143-149. PubMed ID: 28366762
[TBL] [Abstract][Full Text] [Related]
17. Aggressive variant of splenic marginal zone lymphoma characterized using a cancer panel test and treated with rituximab-containing chemotherapy: A case report.
Ishiguro K; Sasaki Y; Takagi Y; Niinuma T; Suzuki H; Tokino T; Hayashi T; Takahashi T; Igarashi T; Matsuno Y
Medicine (Baltimore); 2020 Aug; 99(35):e21938. PubMed ID: 32871937
[TBL] [Abstract][Full Text] [Related]
18. First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
Castelli R; Bergamaschini L; Deliliers GL
Med Oncol; 2017 Dec; 35(2):15. PubMed ID: 29288421
[TBL] [Abstract][Full Text] [Related]
19. [Splenic marginal zone lymphoma complicated by cold agglutinin disease].
Ochi K; Yokoyama K; Ohno N; Ota Y; Tojo A
Rinsho Ketsueki; 2017; 58(2):132-137. PubMed ID: 28321090
[TBL] [Abstract][Full Text] [Related]
20. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.
Tsimberidou AM; Catovsky D; Schlette E; O'Brien S; Wierda WG; Kantarjian H; Garcia-Manero G; Wen S; Do KA; Lerner S; Keating MJ
Cancer; 2006 Jul; 107(1):125-35. PubMed ID: 16700034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
